- NCIt
- C27087
Loading cancer entity…
Loading cancer entity…
Clinical trials
32 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07806617 | Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts | active not recruiting | Phase 2 | 55 | Rush University Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07637734 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)(COVE-3) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT03977753 | Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts(EVAsION) | recruiting | Phase 4 | 162 | Labo'LifeINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07448844 |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials
| Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir |
| recruiting |
| Phase 4 |
| 40 |
| Riphah International UniversityOTHER |
| 1 |
| Aug 7, 2026 |
| clinicaltrials |
| NCT07457918 | Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)(COVE-4) | recruiting | Phase 3 | 600 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07543926 | New Treatment of Common Wart | not yet recruiting | N/A | 70 | Sohag UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05937672 | Cold Atmospheric Plasma Device Extension Study | terminated | Phase 3 | 60 | Medical University of South CarolinaOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07246590 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)(COVE-2) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05889845 | Candin for the Treatment of Common Warts | completed | Phase 3 | 330 | Nielsen BioSciences, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05799157 | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | completed | Phase 2 | 153 | Veradermics, Inc.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06214559 | Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. | completed | N/A | 33 | Swiss Footcare Laboratories - Poderm ProfessionalINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06749665 | Sclerotherapy and Candida Antigen in Treatment of Common Warts | not yet recruiting | N/A | 75 | Sohag UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium(COVE-1) | completed | Phase 2 | 56 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05896215 | OM202JP Clinical Study of KNP2002 | completed | Phase 2 | 159 | KinoPharma Inc.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05070754 | Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca | completed | Phase 4 | 17 | Medical University of South CarolinaOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT01796795 | Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients | suspended | Phase 2 | 102 | G&E Herbal Biotechnology Co., LTDINDUSTRY | 0 | Sep 14, 2023 | clinicaltrials |
| NCT04793529 | Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study | completed | N/A | 60 | Benha UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05115669 | Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts | completed | N/A | 50 | Karo Pharma ABINDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05409365 | Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris | unknown | — | 50 | Sohag UniversityOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT04620785 | Photodynamic Therapy in Treatment of Verrucae | unknown | N/A | 80 | Alexandria UniversityOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT03812510 | Safety Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 426 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03691831 | A Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 502 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Oct 27, 2020 | clinicaltrials |
| NCT03687372 | Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 503 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03183765 | Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts | completed | Phase 4 | 48 | Assiut UniversityOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04288817 | Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts | unknown | Phase 3 | 40 | Assiut UniversityOTHER | 0 | Feb 28, 2020 | clinicaltrials |
| NCT03210337 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts | completed | Phase 2 | 157 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | completed | Phase 2 | 159 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT01609530 | Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy | terminated | N/A | 31 | Trinity Health MichiganOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02748902 | Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands. | completed | Phase 1 | 16 | Neal D. Bhatia, MDOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT02483455 | ALC-919 For The Treatment Of Common Warts | completed | Phase 2 | 21 | Veloce BioPharma LLCINDUSTRY | 1 | Mar 9, 2016 | clinicaltrials |
| NCT01084824 | A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin | completed | N/A | 70 | North Idaho DermatologyOTHER | 1 | Mar 11, 2010 | clinicaltrials |
| NCT00328991 | Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts | completed | N/A | 90 | Minneapolis Veterans Affairs Medical CenterFED | 1 | May 24, 2006 | clinicaltrials |